FDA
-
-
-
-
-
-
-
Anavex receives FDA feedback on Alzheimer's disease drug program
-
-
-
-
-
-
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
-
-
-
-
-
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming Deadline
-
-
-
-
-
-
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against An
-
-
-
-
-
-
-
Anavex Life Sciences Provides an Update on Rett Syndrome Program
-
-
-
-
-
-
-
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
-
-
-
-
-
-
-
Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
-
322,335 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

